---
document_datetime: 2026-01-22 08:10:30
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/abraxane-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: abraxane-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.812177
conversion_datetime: 2026-01-26 20:55:02.106992
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.70.0
  docling-core: 2.60.2
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Abraxane

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | B.II.e.5 Change in pack size of the finished | 20/01/2026                          |                                             | SmPC, Annex                      |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000311114                        | product - B.II.e.5.z Other variation - Accepted                                                                                                                                                                                                                                                       |            |     | II, Labelling and PL             |
|------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------------------------|
| Variation type IA / EMA/VR/0000312985    | A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.b The activities for which the manufacturer/importer is responsible do not include batch release - Accepted                                 | 05/12/2025 | N/A |                                  |
| Variation type IA_IN / EMA/VR/0000301761 | B.V.a.1 Inclusion of a new, updated or amended Plasma Master File in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - B.V.a.1.d Inclusion of an updated/amended Plasma Master File when changes do not affect the properties of the finished product - Accepted | 17/10/2025 | N/A |                                  |
| Variation type IA / EMA/VR/0000301556    | B.II.e.5 Change in pack size of the finished product - B.II.e.5.b Deletion of pack size(s) - Refused                                                                                                                                                                                                  | 14/10/2025 |     | SmPC, Annex II, Labelling and PL |
| Variation type IA_IN / EMA/VR/0000256386 | This was an application for a group of variations. B.V.a.1 Inclusion of a new, updated or amended Plasma Master File in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure)                                                                                          | 11/03/2025 | N/A |                                  |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| - B.V.a.1.d Inclusion of an updated/amended Plasma Master File when changes do not affect the properties of the finished product - Accepted B.V.a.1 Inclusion of a new, updated or amended Plasma Master File in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - B.V.a.1.d Inclusion of an updated/amended Plasma Master File when changes do not affect the properties of the finished product - Accepted   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|